Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tazarotene
Drug ID BADD_D02120
Description Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
Indications and Usage Used to treat psoriasis, acne and sun damaged skin (photodamage).
Marketing Status approved; investigational
ATC Code D05AX05
DrugBank ID DB00799
KEGG ID D01132
MeSH ID C086827
PubChem ID 5381
TTD Drug ID D0BM5G
NDC Product Code 51672-1374; 68308-745; 16110-915; 51014-7755; 45802-442; 0023-0042; 60758-556; 68308-685; 17337-0064; 0713-0804; 17337-0065; 51552-1519; 71052-558; 16110-916; 0023-8335; 0713-0670; 48943-0028; 16110-833; 0187-2098; 51672-1373; 66039-836; 45802-436; 60758-561; 55679-114; 73309-058; 51862-295; 0713-0805; 16110-042; 48943-0027
UNII 81BDR9Y8PS
Synonyms tazarotene | ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate | Tazorac | AGN 190168 | AGN-190168
Chemical Information
Molecular Formula C21H21NO2S
CAS Registry Number 118292-40-3
SMILES CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.0010.003966%Not Available
Application site dermatitis23.03.04.014; 12.07.01.018; 08.02.01.0180.003966%Not Available
Application site erythema12.07.01.001; 08.02.01.001; 23.03.06.0050.010965%Not Available
Application site irritation12.07.01.003; 08.02.01.0030.002644%Not Available
Application site pain12.07.01.004; 08.02.01.0040.009643%Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.0050.002644%Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Burning sensation17.02.06.001; 08.01.09.0290.006610%Not Available
Cheilitis23.03.03.025; 07.05.01.001--
Condition aggravated08.01.03.0040.002644%Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.0030.000778%Not Available
Discomfort08.01.08.003--Not Available
Drug hypersensitivity10.01.01.0010.002644%Not Available
Drug ineffective08.06.01.0060.010576%Not Available
Dry skin23.03.03.0010.002644%
Eczema23.03.04.006--
Erythema23.03.06.0010.013220%Not Available
Facial pain08.01.08.012--
Haemoglobin13.01.05.018--Not Available
Hypersensitivity10.01.03.0030.002644%
Hypertriglyceridaemia14.08.02.001--
Impetigo23.11.02.011; 11.01.12.006--Not Available
Instillation site pain08.02.01.008; 12.07.01.008--Not Available
Leukoderma23.05.02.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
The 1th Page    1 2    Next   Last    Total 2 Pages